FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2201944786> ?p ?o ?g. }

• W2201944786 endingPage "88.e20" @default.
• W2201944786 startingPage "66" @default.
• W2201944786 abstract "To evaluate the influence of renal function on the efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin (TS-071) in Japanese patients with type 2 diabetes mellitus (T2DM).Study 1 was a 52-week, Phase III study to evaluate the efficacy and safety of 2.5 mg/d luseogliflozin (or increased to 5 mg/d) in patients with T2DM with moderate renal impairment. During the initial 24 weeks, efficacy and safety of luseogliflozin were compared with placebo. Study 2 was a pooled analysis of four 52-week, Phase III studies of luseogliflozin, including Study 1, to evaluate the efficacy and safety of luseogliflozin in patients with various degrees of renal function. Patients were stratified into 3 groups by baseline estimated glomerular filtration rate (eGFR): normal renal function (≥90 mL/min/1.73 m(2)), mild impairment (≥60 to <90 mL/min/1.73 m(2)), and moderate impairment (≥30 to <60 mL/min/1.73 m(2)). Patients with moderate impairment were further divided into those with mild-moderate (≥45 to <60 mL/min/1.73 m(2)) and moderate-severe (≥30 to <45 mL/min/1.73 m(2)). In both studies, efficacy end points included changes in glycated hemoglobin (HbA1c) level, fasting plasma glucose (FPG) level, and body weight. The safety end points included adverse events (AEs) and laboratory parameters.In Study 1, HbA1c, FPG, and body weight significantly decreased at Week 24 in patients treated with luseogliflozin compared with patients treated with placebo, with the decrease in these parameters also observed with luseogliflozin at Week 52. The incidence of AEs was similar between groups. In Study 2, 1030 patients were included (normal, 275; mildly impaired, 598; and moderately impaired, 157). At Week 52, HbA1c, FPG, and body weight were significantly decreased from baseline in all groups. In between-group comparisons, the decreases in HbA1c and body weight were significantly smaller in patients with moderate impairment than in those with normal function; however, the HbA1c-lowering efficacy was reduced by nearly half, whereas the efficacy of body weight lowering was not so much diminished in the moderate impairment group. Furthermore, a scatter plot showed that changes in HbA1c were more influenced by baseline HbA1c than by baseline eGFR. The incidence of AEs during 52 weeks was similar among all groups, with the majority being mild.Luseogliflozin improved glycemic control and reduced body weight in all eGFR groups, and its efficacy on HbA1c lowering was reduced in those with moderate renal impairment. Luseogliflozin was well tolerated and safe, with no significant safety issues identified, regardless of baseline eGFR. The study is registered with Clinical Trials Information/JapicCTI of the Japan Pharmaceutical Information Center, and the study registry identification numbers are JapicCTI-111507, JapicCTI-111508, JapicCTI-111509, and JapicCTI-111543." @default.
• W2201944786 created "2016-06-24" @default.
• W2201944786 creator A5006856862 @default.
• W2201944786 creator A5011540038 @default.
• W2201944786 creator A5013977125 @default.
• W2201944786 creator A5021357642 @default.
• W2201944786 creator A5027143314 @default.
• W2201944786 creator A5027382489 @default.
• W2201944786 creator A5036190568 @default.
• W2201944786 creator A5052412166 @default.
• W2201944786 creator A5077189198 @default.
• W2201944786 creator A5089842565 @default.
• W2201944786 date "2016-01-01" @default.
• W2201944786 modified "2023-10-18" @default.
• W2201944786 title "Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus" @default.
• W2201944786 cites W1526927233 @default.
• W2201944786 cites W1561949950 @default.
• W2201944786 cites W1606827863 @default.
• W2201944786 cites W1835352130 @default.
• W2201944786 cites W1980924644 @default.
• W2201944786 cites W1984700778 @default.
• W2201944786 cites W1987004509 @default.
• W2201944786 cites W1990025047 @default.
• W2201944786 cites W1994679938 @default.
• W2201944786 cites W2030192134 @default.
• W2201944786 cites W2036498924 @default.
• W2201944786 cites W2042129134 @default.
• W2201944786 cites W2050346664 @default.
• W2201944786 cites W2052997601 @default.
• W2201944786 cites W2063928700 @default.
• W2201944786 cites W2076152907 @default.
• W2201944786 cites W2077038286 @default.
• W2201944786 cites W2080054505 @default.
• W2201944786 cites W2086240954 @default.
• W2201944786 cites W2111824270 @default.
• W2201944786 cites W2115653936 @default.
• W2201944786 cites W2123946565 @default.
• W2201944786 cites W2127861507 @default.
• W2201944786 cites W2128772657 @default.
• W2201944786 cites W2144383336 @default.
• W2201944786 cites W2150568560 @default.
• W2201944786 cites W2152189242 @default.
• W2201944786 cites W2152413054 @default.
• W2201944786 cites W2156364071 @default.
• W2201944786 cites W2158666727 @default.
• W2201944786 cites W2162492372 @default.
• W2201944786 cites W2337454357 @default.
• W2201944786 cites W4253337782 @default.
• W2201944786 doi "https://doi.org/10.1016/j.clinthera.2015.10.025" @default.
• W2201944786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26718606" @default.
• W2201944786 hasPublicationYear "2016" @default.
• W2201944786 type Work @default.
• W2201944786 sameAs 2201944786 @default.
• W2201944786 citedByCount "53" @default.
• W2201944786 countsByYear W22019447862016 @default.
• W2201944786 countsByYear W22019447862017 @default.
• W2201944786 countsByYear W22019447862018 @default.
• W2201944786 countsByYear W22019447862019 @default.
• W2201944786 countsByYear W22019447862020 @default.
• W2201944786 countsByYear W22019447862021 @default.
• W2201944786 countsByYear W22019447862022 @default.
• W2201944786 countsByYear W22019447862023 @default.
• W2201944786 crossrefType "journal-article" @default.
• W2201944786 hasAuthorship W2201944786A5006856862 @default.
• W2201944786 hasAuthorship W2201944786A5011540038 @default.
• W2201944786 hasAuthorship W2201944786A5013977125 @default.
• W2201944786 hasAuthorship W2201944786A5021357642 @default.
• W2201944786 hasAuthorship W2201944786A5027143314 @default.
• W2201944786 hasAuthorship W2201944786A5027382489 @default.
• W2201944786 hasAuthorship W2201944786A5036190568 @default.
• W2201944786 hasAuthorship W2201944786A5052412166 @default.
• W2201944786 hasAuthorship W2201944786A5077189198 @default.
• W2201944786 hasAuthorship W2201944786A5089842565 @default.
• W2201944786 hasBestOaLocation W22019447861 @default.
• W2201944786 hasConcept C126322002 @default.
• W2201944786 hasConcept C126894567 @default.
• W2201944786 hasConcept C134018914 @default.
• W2201944786 hasConcept C142724271 @default.
• W2201944786 hasConcept C159641895 @default.
• W2201944786 hasConcept C197934379 @default.
• W2201944786 hasConcept C204787440 @default.
• W2201944786 hasConcept C27081682 @default.
• W2201944786 hasConcept C2777180221 @default.
• W2201944786 hasConcept C2777538456 @default.
• W2201944786 hasConcept C2910068830 @default.
• W2201944786 hasConcept C555293320 @default.
• W2201944786 hasConcept C71924100 @default.
• W2201944786 hasConcept C90924648 @default.
• W2201944786 hasConceptScore W2201944786C126322002 @default.
• W2201944786 hasConceptScore W2201944786C126894567 @default.
• W2201944786 hasConceptScore W2201944786C134018914 @default.
• W2201944786 hasConceptScore W2201944786C142724271 @default.
• W2201944786 hasConceptScore W2201944786C159641895 @default.
• W2201944786 hasConceptScore W2201944786C197934379 @default.
• W2201944786 hasConceptScore W2201944786C204787440 @default.
• W2201944786 hasConceptScore W2201944786C27081682 @default.
• W2201944786 hasConceptScore W2201944786C2777180221 @default.
• W2201944786 hasConceptScore W2201944786C2777538456 @default.

• next